8-K: Canopy Growth Reports Q3 Fiscal Year 2025 Financial Results: Storz & Bickel Leads Growth

Canopy Growth's Q3 FY2025 shows progress with strong growth in medical cannabis and Storz & Bickel, alongside the successful launch of Claybourne infused pre-rolls in Canada.

Summary

• Canopy Growth Corporation announced its Q3 FY2025 financial results, with all figures in Canadian dollars unless stated otherwise.
• Net revenue decreased by 5% to $74.8 million compared to Q3 FY2024, but excluding divested businesses, revenue increased by 8%.
• The increase was driven by growth in Canada medical, international markets, and Storz & Bickel.
• Gross margin decreased by 400 bps to 32% due to Claybourne launch costs and increased indirect costs for Storz & Bickel, partially offset by higher-margin medical cannabis sales.
• Operating loss from continuing operations improved by 61% to $24 million, driven by reduced operating expenses.
• Adjusted EBITDA loss improved by 61% year-over-year to $3 million, thanks to cost savings.
• Free cash flow was an outflow of $28 million, a 17% improvement year-over-year, driven by reduced cash interest expenses.
• Total debt decreased to $442 million at December 31, 2024, from $554 million at September 30, 2024, due to an early prepayment of the senior secured term loan.
• Canada cannabis net revenue increased 1% to $41 million, with medical cannabis up 16% and adult-use down 10%.
• International markets net revenue increased 14% to $12 million, driven by growth in Poland and Germany.
• Storz & Bickel net revenue increased 19% to $22 million, driven by holiday sales and online growth.
• Canopy USA completed the acquisition of Acreage Holdings and is integrating its assets, expecting cost savings.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to improvements in EBITDA and free cash flow, debt reduction, and growth in key segments like medical cannabis and Storz & Bickel, despite an overall revenue decrease. The focus on profitability and strategic U.S. expansion also contributes to the positive outlook.

Positives

• Canada medical cannabis net revenue increased 16% year-over-year, driven by larger average order sizes.
• International markets net revenue increased 14% year-over-year, with strong growth in Poland and Germany.
• Storz & Bickel net revenue increased 19% year-over-year, driven by holiday sales and online growth.
• Adjusted EBITDA loss improved by 61% year-over-year, driven by cost savings.
• Free cash flow improved by 17% year-over-year, driven by reduced cash interest expenses.
• Total debt decreased to $442 million, improving the company's financial position.
• Claybourne infused pre-rolls achieved the #3 market share in British Columbia and Ontario within 6 weeks of launch.

Negatives

• Net revenue decreased by 5% compared to the same quarter last year.
• Gross margin decreased by 400 bps to 32% due to launch costs and increased indirect costs.
• Canada adult-use cannabis net revenue declined 10% compared to the same quarter last year.
• Free cash flow remained an outflow of $28 million.

Risks

• The company faces risks associated with forward-looking statements, including regulatory changes, market conditions, and competition.
• There are risks related to the integration of acquired businesses and the success of Canopy USA.
• The company's ability to refinance debt and comply with debt covenants is a risk factor.
• The company's limited operating history and ability to continue as a going concern are also risk factors.

Future Outlook

The company is focused on achieving sustainable profitability and maximizing value creation in key markets and segments, with Canopy USA expected to capitalize on growth opportunities in the U.S. cannabis sector.

Management Comments

• Luc Mongeau, Chief Executive Officer: 'The third quarter highlights that our business has the right ingredients for success, as demonstrated by the continued momentum in our medical cannabis businesses, Storz & Bickel, and the successful introduction of Claybourne infused pre-rolls in Canada. As I step into my role as Chief Executive Officer, I am focused on achieving sustainable profitability while maximizing our ability to create value in the key markets and segments we serve.'
• Judy Hong, Chief Financial Officer: 'The third quarter marked our best Adjusted EBITDA to date, led by strong year-over-year top-line growth in our medical cannabis business and Storz & Bickel, and continued cost discipline. The balance sheet actions taken during the quarter further strengthen our financial position which we believe provides us with flexibility to invest in value creation opportunities.'

Industry Context

The announcement reflects Canopy Growth's efforts to streamline operations and focus on high-growth areas like medical cannabis and strategic acquisitions in the U.S. market, aligning with broader industry trends of consolidation and market expansion.

Comparison to Industry Standards

• Canopy Growth's focus on medical cannabis aligns with companies like Aurora Cannabis, which have also prioritized the higher-margin medical market.
• The expansion into the U.S. market through Canopy USA mirrors strategies employed by other Canadian cannabis companies, such as Tilray, seeking access to the larger U.S. market despite federal restrictions.
• Storz & Bickel's strong performance is comparable to other leading vaporizer brands in the cannabis industry, such as PAX Labs, known for their innovative and high-quality devices.
• The cost-saving measures and debt reduction efforts are consistent with industry-wide initiatives to improve profitability and financial stability, as seen with Organigram and other major players.

Management Changes

Stakeholder Impact

• Shareholders may see potential for long-term growth and profitability due to the company's strategic focus and cost-saving measures.
• Employees may experience changes due to the integration of acquired businesses and restructuring efforts.
• Customers can expect continued innovation and product offerings from brands like Tweed, 7ACRES, and Storz & Bickel.
• Suppliers and creditors may benefit from the company's improved financial position and debt reduction.

Next Steps

• The company will continue to integrate Canopy USA assets and pursue growth opportunities in the U.S. market.
• Canopy Growth will focus on achieving sustainable profitability and maximizing value creation in key markets.
• The company will host a conference call and audio webcast on February 7, 2025, to discuss the financial results.

Key Dates

Keywords

Canopy Growth, financial results, cannabis, Storz & Bickel, medical cannabis, adult-use cannabis, Claybourne, Canopy USA, EBITDA, revenue